NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Xbiotech Inc. XBIT
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-1.49
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-28.2%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 13-year series below
Revenue
Net income
Per share
USD -1.49
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-28.2%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-26.1%
Each USD of equity lost 28 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+4.0%
Change, 10 years−5.5%
The share count grew 4% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 150.1M
total assets, end of FY2025
Total assetsUSD 150.1M
EquityUSD 140.3M
CashUSD 125.6M
Current ratio16.01×
Equity funds 94% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
·
·
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Operating income $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.7
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−1.49
−1.26
−0.81
−1.08
−0.58
−0.36
14.44
−0.59
−0.95
−1.63
−1.22
−0.90
−0.45
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
−0
−431
−0
0
·
·
·
·
·
·
ROE %
−28.2
−19.2
−10.7
−12.9
−5.6
−2.0
167.8
−41.6
−55.6
−65.1
−46.3
−62.7
−97.1
Shares out B
0.03
0.03
0.03
0.03
0.03
0.03
0.04
0.04
0.04
0.03
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed